OnKure Therapeutics, Inc. OKUR
2.90
(0.03)
(1.02%)
as of 25 Sep
- Market cap
- $118.7M
- P/E
- 0.0×
Follow OKUR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
10.28 | 10.73 | 4.64 | 14.93 | 24.79 | 12.01 | 8.64 | — |
Net Debt/EBITDA |
0.95 | 2.07 | 0.82 | 1.85 | 3.73 | 2.74 | 1.60 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.87 | 0.97 | 0.98 | 0.91 | 0.96 | 0.95 | 1.01 | — |
Capex/Depreciation |
(0.06) | (0.06) | (0.44) | 0.49 | (0.79) | (1.20) | 0.06 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (74.39%) | (5,304.43%) | 3,772.54% | (42.04%) | (75.68%) | 59.67% | 38.12% | — | |
| (67.24%) | (69.93%) | (49.07%) | (39.63%) | (38.01%) | (48.22%) | (97.52%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(107.17%) | (50.89%) | (126.50%) | (52.12%) | (26.92%) | (38.53%) | (55.16%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(3.84) | (14.84) | (122.59) | (19.48) | (21.04) | (91.52) | (64.26) | — |
Cash per Share |
4.37 | 32.13 | 105.27 | 41.30 | 81.39 | 264.36 | 127.76 | — |
Shareholders Equity per Share |
4.16 | 30.12 | 98.60 | 40.81 | 81.14 | 249.53 | 115.63 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
4.16 | 30.12 | 98.60 | 40.81 | 81.14 | 249.53 | 115.63 | — |
Free Cash Flow |
(51.87) | (51.17) | (34.79) | (47.71) | (38.18) | (18.56) | (12.52) | — |
Working Capital |
54.92 | 102.47 | 26.48 | 99.23 | 147.53 | 50.45 | 22.47 | — |
Capital Expenditures |
(0.05) | (0.05) | (0.25) | (0.35) | (0.20) | (0.02) | (0.01) | — |
Net Current Asset Value |
54.91 | 101.92 | 26.02 | 98.14 | 146.92 | 50.41 | 22.43 | — |
| Other line items | ||||||||
Quick Ratio |
9.97 | 10.52 | 4.10 | 14.20 | 23.81 | 11.71 | 8.47 | — |
Depreciation/Fixed assets |
1.34 | 0.78 | 0.39 | (1.57) | 1.19 | 0.29 | (1.46) | — |
Cash ROIC |
(45.51%) | (24.30%) | (62.18%) | (23.77%) | (12.95%) | (17.85%) | (26.55%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.83) | (14.83) | (121.73) | (19.33) | (20.94) | (91.40) | (64.22) | — |
Capex per Share |
0.00 | (0.02) | (0.87) | (0.14) | (0.11) | (0.12) | (0.04) | — |
Average Payables |
2.20 | 3.19 | 2.66 | 1.96 | 1.47 | 0.73 | 0.73 | — |
Average Assets |
88.51 | 75.32 | 71.96 | 131.10 | 104.62 | 40.36 | 12.75 | — |
Average Common Equity |
80.01 | 0.99 | (0.94) | 123.59 | 52.55 | (32.62) | (32.62) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates